Wave Life Sciences Future Growth
Future criteria checks 2/6
Wave Life Sciences is forecast to grow earnings and revenue by 13.3% and 30.9% per annum respectively while EPS is expected to grow by 19.5% per annum.
Key information
13.3%
Earnings growth rate
19.5%
EPS growth rate
Pharmaceuticals earnings growth | 23.6% |
Revenue growth rate | 30.9% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 09 Aug 2024 |
Recent future growth updates
Recent updates
We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate
Aug 05Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now
Jun 25We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Apr 09Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche
Mar 09Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues
Mar 03We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow
Sep 13Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially
May 08Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely
Mar 30Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?
Jan 20Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates
Nov 11Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?
Aug 12Wave Life Sciences Q2 2022 Earnings Preview
Aug 10Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?
Apr 21Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?
Jan 11We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully
Sep 24What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates
Aug 07Wave Life Sciences posts proof-of-concept data from genetic disorder study
Jun 02Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates
May 15Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade
Apr 02Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 89 | -138 | -188 | -150 | 7 |
12/31/2025 | 56 | -156 | -147 | -135 | 8 |
12/31/2024 | 62 | -138 | -138 | -150 | 7 |
6/30/2024 | 111 | -73 | -130 | -129 | N/A |
3/31/2024 | 113 | -62 | -139 | -138 | N/A |
12/31/2023 | 113 | -58 | -21 | -19 | N/A |
9/30/2023 | 85 | -85 | -21 | -20 | N/A |
6/30/2023 | 37 | -131 | -12 | -11 | N/A |
3/31/2023 | 15 | -151 | -4 | -2 | N/A |
12/31/2022 | 4 | -162 | -129 | -128 | N/A |
9/30/2022 | 4 | -153 | -103 | -101 | N/A |
6/30/2022 | 40 | -120 | -105 | -104 | N/A |
3/31/2022 | 43 | -118 | -85 | -84 | N/A |
12/31/2021 | 41 | -122 | -90 | -89 | N/A |
9/30/2021 | 49 | -116 | -114 | -113 | N/A |
6/30/2021 | 16 | -143 | -106 | -105 | N/A |
3/31/2021 | 16 | -145 | -135 | -134 | N/A |
12/31/2020 | 20 | -150 | -117 | -116 | N/A |
9/30/2020 | 13 | -178 | -148 | -146 | N/A |
6/30/2020 | 13 | -196 | -172 | -169 | N/A |
3/31/2020 | 17 | -197 | -168 | -164 | N/A |
12/31/2019 | 16 | -194 | -192 | -188 | N/A |
9/30/2019 | 17 | -175 | -166 | -160 | N/A |
6/30/2019 | 19 | -162 | -154 | -145 | N/A |
3/31/2019 | 16 | -156 | -50 | -41 | N/A |
12/31/2018 | 14 | -147 | -33 | -23 | N/A |
9/30/2018 | 12 | -140 | -23 | -13 | N/A |
6/30/2018 | 9 | -127 | -20 | -7 | N/A |
3/31/2018 | 5 | -116 | N/A | -99 | N/A |
12/31/2017 | 4 | -102 | N/A | -84 | N/A |
9/30/2017 | 3 | -90 | N/A | -74 | N/A |
6/30/2017 | 3 | -82 | N/A | -63 | N/A |
3/31/2017 | 2 | -69 | N/A | -42 | N/A |
12/31/2016 | 1 | -56 | N/A | -32 | N/A |
9/30/2016 | 1 | -44 | N/A | -25 | N/A |
6/30/2016 | 0 | -31 | N/A | -16 | N/A |
3/31/2016 | 0 | -24 | N/A | -18 | N/A |
12/31/2015 | 0 | -19 | N/A | -13 | N/A |
9/30/2015 | 0 | -14 | N/A | -7 | N/A |
6/30/2015 | 0 | -10 | N/A | -5 | N/A |
3/31/2015 | 0 | -8 | N/A | -5 | N/A |
12/31/2014 | N/A | -5 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: WVE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: WVE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: WVE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: WVE's revenue (30.9% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: WVE's revenue (30.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if WVE's Return on Equity is forecast to be high in 3 years time